ArticleCancer research communications2025
Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade-Treated Advanced Melanoma: A Retrospective Analysis.
Article in Cancer research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced melanoma, characterized by its aggressiveness and genomic complexity, demands improved prognostic and therapeutic strategies, particularly for patients with limited response to immune checkpoint blockade (ICB). Gene fusions, proposed as enhancers of tumor immunogenicity through neoantigens, also reflect chromosomal instability, which influences tumor evolution and therapy outcomes. However, their impact on melanoma remains unexplored. By retrospectively analyzing baseline tumors from 222 ICB-treated patients, we found a high tumor fusion burden (TFB-H) correlation with poor RECIST response, reduced overall survival (time-dependent ROC > 0.6, P << 0.01), and increased mortality risk (HR = 2, P < 0.01). TFB-H was found to be strongly associated with chromosomal instability (β = 0.72, P < 0.01), heightened proliferation, and diminished immune cytolytic activity. TFB-H was also linked to poor prognosis and immune impairment in nonadvanced melanoma tumors (n = 441) that have not received ICB treatment. These findings suggest that TFB-H tumors may exhibit an aggressive phenotype insensitive to ICB, probably due to immune evasion caused by intratumoral heterogeneity. Additionally, we identified targetable fusions, such as KIAA1549::BRAF, which represent therapeutic opportunities for advanced melanoma, including novel type II RAF inhibitors with potent activity against kinase fusions. Integrating gene fusion profiling into clinical practice may guide precision medicine strategies to overcome the limitations of ICB in advanced melanoma, offering prognostic insights and expanding therapeutic options, particularly with emerging fusion-specific inhibitors. SIGNIFICANCE: The evidence of this work supports the idea that gene fusion profiling may serve as both a prognostic marker and a guide for alternative therapeutic strategies, including targeted fusion inhibitors, in patients less likely to benefit from ICB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.